Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts
Annals of the Rheumatic Diseases · 2026-05 · 85 (5) · 921-931
DOI: 10.1016/j.ard.2025.10.015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-05. Verfasst von Frank Buttgereit und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Prednisolone, Polymyalgia Rheumatica, Glucocorticoids, 11-beta-Hydroxysteroid Dehydrogenase Type 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: Glucocorticoids effectively treat many diseases, but toxicity limits their utility. We aimed to learn whether, by reducing active intracellular glucocorticoid exposures, the 11β-hydroxysteroid dehydrogenase type 1 inhibitor clofutriben could selectively reduce glucocorticoid efficacy but reduce toxicity more strongly. We hypothesised that by increasing the prednisolone dose, it might be possible to restore efficacy back to the original level, thereby improving the benefit-risk profile. METHODS: In sequential cohorts, adults with polymyalgia rheumatica received (single blind) prednisolone 10 mg/d with placebo for 2 weeks, then clofutriben with either prednisolone 10, 15, 20, or 30 mg/d for 2 weeks. RESULTS: Forty-nine and 47 participants completed each trial period with evaluable data. Five who received prednisolone 10 mg/d with clofutriben experienced clinical relapse. No clinical relapses occurred during other treatments. Participants reported more severe symptoms and physical disability when prednisolone 10 mg/d or 15 mg/d, but not 20 mg/d or 30 mg/d, was given with clofutriben. Inflammatory biomarkers followed a similar pattern. Across all prednisolone doses, clofutriben coadministration mitigated glucocorticoid-related adverse effects on biomarkers of bone turnover, lipid metabolism, hypercoagulability, and cardiovascular and adrenal function. CONCLUSIONS: Further trials to assess clofutriben's potential to improve the benefit-risk profile of prednisolone are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Hamburger Rheuma Forschungszentrum II, Hamburg, Germany.
- Ruhr-Universität Bochum, Bochum, Germany; Rheumazentrum Ruhrgebiet, Herne, Germany.
- Schwerpunktpraxis für Rheumatologie und Gastroenterologie München, München, Germany.
- Internistische Praxisgemeinschaft Rheumatologie Nephrologie Erlangen, Erlangen, Germany.
- Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Buttgereit, F., Everding, A., Andreica, I., Kellner, H. L., Schuch, F., Weyand, C., Stewart, P. M., Merkel, P. A., Dejaco, C., Czerwiec, F. S., Desai, K., & Katz, D. A. (2026). Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Annals of the Rheumatic Diseases, 85(5), 921-931. https://doi.org/10.1016/j.ard.2025.10.015
Vancouver
Buttgereit F, Everding A, Andreica I, Kellner HL, Schuch F, Weyand C, et al. Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Annals of the Rheumatic Diseases. 2026;85(5):921-931. doi:10.1016/j.ard.2025.10.015
BibTeX
@article{Buttgereit2026,
author = {Buttgereit, Frank and Everding, Andrea and Andreica, Ioana and Kellner, Herbert L and Schuch, Florian and Weyand, Cornelia and Stewart, Paul M and Merkel, Peter A and Dejaco, Christian and Czerwiec, Frank S and Desai, Ketan and Katz, David A},
title = {Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {5},
pages = {921--931},
doi = {10.1016/j.ard.2025.10.015}
}
EUVIMED